A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Part of paid clinical trials in La Jolla, California.
- Sponsor
- Insmed Gene Therapy LLC
- Study ID
- NCT07290062
- Phase
- PHASE1
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 79 Years
- Healthy Volunteers
- Not accepted
Interventions
- INS1202 — GENETICSuspension for injection.
Study Details
The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.
Key Dates
- Start date
- Jan 9, 2026
- Status verified
- May 2026
- Primary completion
- Mar 31, 2030
- Completion
- Mar 31, 2030
Study Design
- Enrollment
- 23 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1Participants with sporadic amyotrophic lateral sclerosis (sALS) will be administered INS1202, IT injection at dose level 1 on Day 1.
- Experimental: Cohort 2Participants with either sALS or SOD1-ALS, will be administered INS1202 via IT injection at dose level 2 on Day 1.
- Experimental: Cohort 3Participants with either sALS or SOD1-ALS, will be administered INS1202 via IT injection at dose level 3 on Day 1.
Primary Outcome Measure
Incidence and Severity of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to 48 weeks ]
Central Contacts
- Insmed Medical Information1-844-446-7633
Locations (5)
Find similar trials in La Jolla, CA
Related Studies
- BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With TetraplegiaRecruiting · Leigh R. Hochberg, MD, PhD. · Sacramento, California
- Phenotype, Genotype & Biomarkers in ALS and Related DisordersEnrolling By Invitation · University of Miami · Palo Alto, California
- Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsPHASE3 · Recruiting · AB Science · Birmingham, Alabama
- Clinical Procedures to Support Research in ALSRecruiting · University of Miami · Irvine, California